Drug Induced Liver Injury: Highlights and Controversies in the 2023 Literature

Harjit Singh (), Bryce F. Kunkle, Angela R. Troia, Advait M. Suvarnakar, Ade C. Waterman, Yadana Khin, Serena Y. Korkmaz, Corinne E. O’Connor and James H. Lewis
Additional contact information
Harjit Singh: Medstar Georgetown University Hospital
Bryce F. Kunkle: Medstar Georgetown University Hospital
Angela R. Troia: Medstar Georgetown University Hospital
Advait M. Suvarnakar: Georgetown University School of Medicine
Ade C. Waterman: Medstar Georgetown University Hospital
Yadana Khin: Medstar Georgetown University Hospital
Serena Y. Korkmaz: Medstar Georgetown University Hospital
Corinne E. O’Connor: Medstar Georgetown University Hospital
James H. Lewis: Medstar Georgetown University Hospital

Drug Safety, 2025, vol. 48, issue 5, No 2, 455-488

Abstract: Abstract Drug-induced liver injury (DILI) remains an active field of clinical research and investigation with more than 4700 publications appearing in 2023 relating to hepatotoxicity of all causes and injury patterns. As in years past, we have attempted to identify and summarize highlights and controversies from the past year’s literature. Several new and novel therapeutic agents were approved by the US Food and Drug Administration (FDA) in 2023, a number of which were associated with significant hepatotoxicity. Updates in the diagnosis and management of DILI using causality scores as well as newer artificial intelligence-based methods were published. Details of newly established hepatotoxins as well as updated information on previously documented hepatotoxic drugs is presented. Significant updates in treatment of DILI were also included as well as reports related to global DILI registries.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-025-01514-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:48:y:2025:i:5:d:10.1007_s40264-025-01514-z

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-025-01514-z

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().